Kellin Chemicals' API site refused FDA inspection, so FDA calls its drugs adulterated.
What happened
FDA scheduled an inspection of Kellin Chemicals' drug manufacturing site from July 7 to July 11, 2025, and the company's U.S. agent told FDA the firm refused the preannounced inspection. FDA cites the refusal as making the company's drugs adulterated under the FD&C Act. The firm is registered as a supplier of active pharmaceutical ingredients (APIs) to finished-drug makers that sell to the U.S. market.
What FDA found
The company refused to let FDA inspect its drug manufacturing facility after FDA gave notice of a planned inspection.
Section 501(j) of the FD&C Act, 21 U.S.C. 351(j)Because the company refused inspection, FDA treats the drugs made there as adulterated.
Section 501(j) of the FD&C Act, 21 U.S.C. 351(j)FDA may detain or refuse U.S. shipments that appear adulterated or misbranded.
Section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3)
What FDA wants
FDA asks the company to respond in writing within 15 working days and says it may provide more information or request an inspection; FDA also recommends informing U.S. customers about the letter.
Who should pay attention
- U.S. finished-drug manufacturers using Kellin APIs
- brands and suppliers sourcing APIs from China
- regulatory teams tracking supplier inspection status
This is a summary. Read the original letter on fda.gov.